SEC Company Response from Enlivex Ltd. (ENLV) (CIK 0001596812) (ENLV) — Jul 28, 2014
Enlivex Ltd. (ENLV) (CIK 0001596812)
Date: July 28, 2014 · CIK: 0001596812 · Accession: 0001144204-14-045183
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-193824
Letter
Bio Blast Pharma Ltd.
37 Dereh Menachem Begin St., 15th Floor
Tel Aviv 6522042 Israel
July 28, 2014
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE: Bio Blast Pharma Ltd. (CIK 0001596812)
Registration Statement No. 333-193824 on Form F-1
Ladies and Gentlemen:
Bio Blast Pharma Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on July 30, 2014, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant acknowledges that:
· should the Securities and Exchange Commission (the “Commission”) or its staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
· the action of the Commission or its staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
· The Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
Very truly yours,
BIO BLAST PHARMA LTD.
Show Raw Text
CORRESP
1
filename1.htm
Bio Blast Pharma Ltd.
37 Dereh Menachem Begin St., 15th
Floor
Tel Aviv 6522042 Israel
July 28, 2014
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Bio Blast Pharma Ltd. (CIK 0001596812)
Registration Statement No. 333-193824 on Form F-1
Ladies and Gentlemen:
Bio Blast Pharma Ltd.
(the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement
pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become
effective on July 30, 2014, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant acknowledges
that:
· should the Securities and Exchange Commission
(the “Commission”) or its staff, acting pursuant to delegated authority, declare the Registration Statement
effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
· the action of the Commission or its staff,
acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from
its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
· The Registrant may not assert staff comments
and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.
The Registrant
understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement
as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the
proposed public offering of the securities specified in the Registration Statement.
Very truly yours,
BIO BLAST PHARMA LTD.
By: /s/ Dr. Dalia Megiddo
Dr. Dalia Megiddo, Chief Executive
Officer